HOME >> MEDICINE >> NEWS
Low tar cigarettes do not cut lung cancer risk

The risk of lung cancer is no different in people who smoke medium tar cigarettes, low tar cigarettes, or very low tar cigarettes, concludes new research from the United States.

Researchers analysed the relation between the tar rating of the brand of cigarette smoked in 1982 and death from lung cancer over six years among 364,239 men and 576,535 women aged 30 years or more.

Irrespective of the tar level of their current brand, all current smokers had a far greater risk of lung cancer than people who had never smoked or who had quit.

Men and women who smoked very low tar (7 mg or less) and low tar (8-14 mg) brands had risks of lung cancer indistinguishable from those who smoked medium tar (15-21 mg) brands. This pattern did not change after demographic factors, dietary habits, and occupational and medical histories were taken into account.

Men and women who smoked non-filtered cigarettes with tar ratings of 22 mg or more had even higher risks of lung cancer.

These findings are consistent with other evidence that people smoke low tar cigarettes more intensively, and challenge the assumption that the link between tar rating and lung cancer risk is necessarily linear, say the authors.

They suggest that reducing the use of high tar non-filter cigarettes may provide limited public health benefits in those countries where these products are commonly used.


'"/>

Contact: Linda Millington
pressoffice@bma.org.uk
44-0-20-7383-6473
BMJ-British Medical Journal
8-Jan-2004


Page: 1

Related medicine news :

1. Tobacco-company-sponsored parties with free cigarettes may encourage students to start smoking
2. Majority of cigarettes in the US smoked by nicotine-dependent or psychiatrically ill persons
3. Activism prompts teen smokers to cut back on cigarettes, Stanford study finds
4. Heavy smokers see cigarettes as friends
5. UNC study shows Internet offers youths easy way to buy cigarettes
6. Rising cost of cigarettes may help smokers honor new years resolution to quit
7. Carcinogen in cigarettes causes mutation linked to lung cancer
8. Brain chemicals can thwart desire to smoke cigarettes
9. It is easy for adolescents to purchase cigarettes illegally in North Carolina
10. Hormonal treatment improves survival in high-risk prostate cancer patients
11. International breast cancer prevention study launches in the United States and Canada

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Low tar cigarettes not cut lung cancer risk

(Date:6/18/2013)... Alabama (PRWEB) June 19, 2013 Consumer ... and two other law firms have launched a new ... injuries caused by dialysis. The website is http://www.DialysisLawsuitAttorneys.com ... was time to begin offering legal services to people ... drugs GranuFlo and NaturaLyte, or who may have suffered ...
(Date:6/18/2013)... 19, 2013 oBand Surgery Centers, a ... holding complimentary weight loss seminars in Los Angeles this ... be accessed at their official website. oBand Surgery Centers ... time. Their highly skilled panel of surgeons and dedicated ... , A senior executive working with oBand Surgery Centers ...
(Date:6/18/2013)... As a sponsor of the 2013 Fourth of July ... Lake Meridian Chiropractic want you to get out and celebrate! ... event and are excited to be involved. “My husband and I ... loved going to the Kent Splash event. It's a tradition that ... to financially support this fun day.” , The 2013 ...
(Date:6/18/2013)... IL (PRWEB) June 18, 2013 Exposed Skin ... helping thousands of acne suffers of all ages finally achieve ... other acne treatment products, this new acne clearing system combines ... acne, and prevent new acne from forming. , ... ExposedSkinCareReview.org believes these products are some of the most effective ...
(Date:6/18/2013)... (PRWEB) June 19, 2013 "What if ... a day could boost your health and well-being? Well, ... founder of Sublime Beauty®. "It is called Skin ... centuries but became a lost art. Now, people are ... about Skin Brushing, and so do certain health conscious ...
Breaking Medicine News(10 mins):Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2Health News:Lake Meridian Chiropractic of Kent, WA to Sponsor the Fireworks Finale at 15th Annual Fourth of July Splash 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: